Moreau, P, Kumar, S K, San Miguel, J, Davies, F, Zamagni, E, Bahlis, N, Ludwig, H, Mikhael, J, Terpos, E, Schjesvold, F, Martin, T, Yong, K, Durie, B G M, Facon, T, Jurczyszyn, A, Sidana, S, Raje, N, van de Donk, N, Lonial, S, Cavo, M, Kristinsson, S Y, Lentzsch, S, Hajek, R, Anderson, K C, João, C, Einsele, H, Sonneveld, P, Engelhardt, M, Fonseca, R, Vangsted, A, Weisel, K, Baz, R, Hungria, V, Berdeja, J G, Leal da Costa, F, Maiolino, A, Waage, A, Vesole, D H, Ocio, E M, Quach, H, Driessen, C, Bladé, J, Leleu, X, Riva, E, Bergsagel, P L, Hou, J, Chng, W J, Mellqvist, U H, Dytfeld, D, Harousseau, J L, Goldschmidt, H, Laubach, J, Munshi, N C, Gay, F, Beksac, M, Costa, L J, Kaiser, M, Hari, P, Boccadoro, M, Usmani, S Z, Zweegman, S, Holstein, S, Sezer, O, Harrison, S, Nahi, H, Cook, G, Mateos, M V, Rajkumar, S V, Dimopoulos, M A & Richardson, P G 2021, ' Treatment of relapsed and refractory multiple myeloma : recommendations from the International Myeloma Working Group ', The Lancet Oncology, vol. 22, no. 3, pp. e105-e118 . https://doi.org/10.1016/S1470-2045(20)30756-7 The Lancet Oncology, 22(3), e105-e118. Lancet Publishing Group